Cargando…
Identifying individualized prognostic signature and unraveling the molecular mechanism of recurrence in early-onset colorectal cancer
BACKGROUND: The incidence and mortality of early-onset colorectal cancer (EOCRC; < 50 years old) is increasing worldwide, with a high recurrence rate. The inherent heterogeneity of EOCRC makes its treatment challenging. Hence, to further understand the biology and reveal the molecular mechanisms...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658991/ https://www.ncbi.nlm.nih.gov/pubmed/37986009 http://dx.doi.org/10.1186/s40001-023-01491-y |
_version_ | 1785148271270821888 |
---|---|
author | Yang, Jia Zhao, Yuting Yuan, Rongqiang Wang, Yongtong Wang, Shiyi Chang, Zhiqiang Zhao, Wenyuan |
author_facet | Yang, Jia Zhao, Yuting Yuan, Rongqiang Wang, Yongtong Wang, Shiyi Chang, Zhiqiang Zhao, Wenyuan |
author_sort | Yang, Jia |
collection | PubMed |
description | BACKGROUND: The incidence and mortality of early-onset colorectal cancer (EOCRC; < 50 years old) is increasing worldwide, with a high recurrence rate. The inherent heterogeneity of EOCRC makes its treatment challenging. Hence, to further understand the biology and reveal the molecular mechanisms of EOCRC, a recurrence risk signature is needed to guide clinical management. METHODS: Based on the relative expression orderings (REOs) of genes in each sample, a prognostic signature was developed and validated utilizing multiple independent datasets. The underlying molecular mechanisms between distinct prognostic groups were explored via integrative analysis of multi-omics data. RESULTS: The prognostic signature consisting of 6 gene pairs (6-GPS) could predict the recurrence risk for EOCRC at the individual level. High-risk EOCRC classified by 6-GPS showed a poor prognosis but a good response to adjuvant chemotherapy. Moreover, high-risk EOCRC was characterized by epithelial-mesenchymal transition (EMT) and enriched angiogenesis, and had higher mutation burden, immune cell infiltration, and PD-1/PD-L1 expression. Furthermore, we identified four genes associated with relapse-free survival in EOCRC, including SERPINE1, PECAM1, CDH1, and ANXA1. They were consistently differentially expressed at the transcriptome and proteome levels between high-risk and low-risk EOCRCs. They were also involved in regulating cancer progression and immune microenvironment in EOCRC. Notably, the expression of SERPINE1 and ANXA1 positively correlated with M2-like macrophage infiltration. CONCLUSION: Our results indicate that 6-GPS can robustly predict the recurrence risk of EOCRC, and that SERPINE1, PECAM1, CDH1, and ANXA1 may serve as potential therapeutic targets. This study provides valuable information for the precision treatment of EOCRC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40001-023-01491-y. |
format | Online Article Text |
id | pubmed-10658991 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-106589912023-11-20 Identifying individualized prognostic signature and unraveling the molecular mechanism of recurrence in early-onset colorectal cancer Yang, Jia Zhao, Yuting Yuan, Rongqiang Wang, Yongtong Wang, Shiyi Chang, Zhiqiang Zhao, Wenyuan Eur J Med Res Research BACKGROUND: The incidence and mortality of early-onset colorectal cancer (EOCRC; < 50 years old) is increasing worldwide, with a high recurrence rate. The inherent heterogeneity of EOCRC makes its treatment challenging. Hence, to further understand the biology and reveal the molecular mechanisms of EOCRC, a recurrence risk signature is needed to guide clinical management. METHODS: Based on the relative expression orderings (REOs) of genes in each sample, a prognostic signature was developed and validated utilizing multiple independent datasets. The underlying molecular mechanisms between distinct prognostic groups were explored via integrative analysis of multi-omics data. RESULTS: The prognostic signature consisting of 6 gene pairs (6-GPS) could predict the recurrence risk for EOCRC at the individual level. High-risk EOCRC classified by 6-GPS showed a poor prognosis but a good response to adjuvant chemotherapy. Moreover, high-risk EOCRC was characterized by epithelial-mesenchymal transition (EMT) and enriched angiogenesis, and had higher mutation burden, immune cell infiltration, and PD-1/PD-L1 expression. Furthermore, we identified four genes associated with relapse-free survival in EOCRC, including SERPINE1, PECAM1, CDH1, and ANXA1. They were consistently differentially expressed at the transcriptome and proteome levels between high-risk and low-risk EOCRCs. They were also involved in regulating cancer progression and immune microenvironment in EOCRC. Notably, the expression of SERPINE1 and ANXA1 positively correlated with M2-like macrophage infiltration. CONCLUSION: Our results indicate that 6-GPS can robustly predict the recurrence risk of EOCRC, and that SERPINE1, PECAM1, CDH1, and ANXA1 may serve as potential therapeutic targets. This study provides valuable information for the precision treatment of EOCRC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40001-023-01491-y. BioMed Central 2023-11-20 /pmc/articles/PMC10658991/ /pubmed/37986009 http://dx.doi.org/10.1186/s40001-023-01491-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Yang, Jia Zhao, Yuting Yuan, Rongqiang Wang, Yongtong Wang, Shiyi Chang, Zhiqiang Zhao, Wenyuan Identifying individualized prognostic signature and unraveling the molecular mechanism of recurrence in early-onset colorectal cancer |
title | Identifying individualized prognostic signature and unraveling the molecular mechanism of recurrence in early-onset colorectal cancer |
title_full | Identifying individualized prognostic signature and unraveling the molecular mechanism of recurrence in early-onset colorectal cancer |
title_fullStr | Identifying individualized prognostic signature and unraveling the molecular mechanism of recurrence in early-onset colorectal cancer |
title_full_unstemmed | Identifying individualized prognostic signature and unraveling the molecular mechanism of recurrence in early-onset colorectal cancer |
title_short | Identifying individualized prognostic signature and unraveling the molecular mechanism of recurrence in early-onset colorectal cancer |
title_sort | identifying individualized prognostic signature and unraveling the molecular mechanism of recurrence in early-onset colorectal cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658991/ https://www.ncbi.nlm.nih.gov/pubmed/37986009 http://dx.doi.org/10.1186/s40001-023-01491-y |
work_keys_str_mv | AT yangjia identifyingindividualizedprognosticsignatureandunravelingthemolecularmechanismofrecurrenceinearlyonsetcolorectalcancer AT zhaoyuting identifyingindividualizedprognosticsignatureandunravelingthemolecularmechanismofrecurrenceinearlyonsetcolorectalcancer AT yuanrongqiang identifyingindividualizedprognosticsignatureandunravelingthemolecularmechanismofrecurrenceinearlyonsetcolorectalcancer AT wangyongtong identifyingindividualizedprognosticsignatureandunravelingthemolecularmechanismofrecurrenceinearlyonsetcolorectalcancer AT wangshiyi identifyingindividualizedprognosticsignatureandunravelingthemolecularmechanismofrecurrenceinearlyonsetcolorectalcancer AT changzhiqiang identifyingindividualizedprognosticsignatureandunravelingthemolecularmechanismofrecurrenceinearlyonsetcolorectalcancer AT zhaowenyuan identifyingindividualizedprognosticsignatureandunravelingthemolecularmechanismofrecurrenceinearlyonsetcolorectalcancer |